EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
News|Articles|August 14, 2013
Weight Loss and Abdominal Pain in Diabetic Man: What Test?
What study would you order to determine the cause of progressively worsening crampy abdominal pain and unintentional weight loss in an older patient with diabetes?
Advertisement
A 74-year-old man with diabetes presents with a chief complaint of crampy abdominal pain, particularly following meals, that has been progressively worsening over the past 6 months. Since that time, he has unintentionally lost 8 lb. His stools have been loose, but otherwise unremarkable. Which of the following studies would reveal the most likely diagnosis?
A. Esophagogastroduodenoscopy
B. RUQ ultrasonogram
C Colonoscopy
D. CT angiography of the abdomen
Advertisement
Related to this article
The FDA has approved insulin efsitora alfa-gobe (Onswik) for adults with type 2 diabetes.
New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
New research underscores the need for public health interventions to improve the microbial and fiber content of diets in the US.
Advertisement
Advertisement
Trending on Patient Care Online
1
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
2
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
3
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
4
Detecting Atrial Fibrillation in Primary Care: Warning Signs and Modifiable Risk Factors
5